APO Research
Talk to an analyst

APO RESEARCH · REPORT

DTaP and Tdap Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global DTaP and Tdap Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025191 pages

Choose your research edition.

Industry ResearchDTaP and Tdap Vaccines Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal DTaP and Tdap Vaccines Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal DTaP and Tdap Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DTaP and Tdap Vaccines Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal DTaP and Tdap Vaccines Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global DTaP and Tdap Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for DTaP and Tdap Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DTaP and Tdap Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DTaP and Tdap Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for DTaP and Tdap Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of DTaP and Tdap Vaccines include Johnson & Johnson, Novartis AG, Lanzhou Institute of Biological Products Co., Ltd, Pfizer Inc, GlaxoSmithKline, AstraZeneca, Seqirus, Sanofi Pasteur and Protein Sciences Corporation, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global DTaP and Tdap Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DTaP and Tdap Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DTaP and Tdap Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the DTaP and Tdap Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

DTaP and Tdap Vaccines Segment by Company

Johnson & Johnson

Novartis AG

Lanzhou Institute of Biological Products Co., Ltd

Pfizer Inc

GlaxoSmithKline

AstraZeneca

Seqirus

Sanofi Pasteur

Protein Sciences Corporation

Merck Sharp & Dohme Corp

Emergent BioSolutions Inc

Astellas Pharma US, Inc

DTaP and Tdap Vaccines Segment by Type

Tdap

DTaP

Td

DTaP and Tdap Vaccines Segment by Application

Adult

Pediatric

DTaP and Tdap Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DTaP and Tdap Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DTaP and Tdap Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DTaP and Tdap Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DTaP and Tdap Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of DTaP and Tdap Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of DTaP and Tdap Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. DTaP and Tdap Vaccines Industry Trends Table 2. DTaP and Tdap Vaccines Industry Drivers Table 3. DTaP and Tdap Vaccines Industry Opportunities and Challenges Table 4. DTaP and Tdap Vaccines Industry Restraints Table 5. Global DTaP and Tdap Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global DTaP and Tdap Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global DTaP and Tdap Vaccines Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global DTaP and Tdap Vaccines Sales Market Share by Manufacturers Table 9. Global DTaP and Tdap Vaccines Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global DTaP and Tdap Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global DTaP and Tdap Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global DTaP and Tdap Vaccines Manufacturers, Product Type & Application Table 13. Global DTaP and Tdap Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global DTaP and Tdap Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Tdap Table 17. Major Manufacturers of DTaP Table 18. Major Manufacturers of Td Table 19. Global DTaP and Tdap Vaccines Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global DTaP and Tdap Vaccines Sales by Type (2021-2026) & (W Units) Table 21. Global DTaP and Tdap Vaccines Sales by Type (2027-2032) & (W Units) Table 22. Global DTaP and Tdap Vaccines Sales Market Share by Type (2021-2026) Table 23. Global DTaP and Tdap Vaccines Sales Market Share by Type (2027-2032) Table 24. Global DTaP and Tdap Vaccines Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global DTaP and Tdap Vaccines Revenue by Type (2021-2026) & (W Units) Table 26. Global DTaP and Tdap Vaccines Revenue by Type (2027-2032) & (W Units) Table 27. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2021-2026) Table 28. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Adult Table 30. Major Manufacturers of Pediatric Table 31. Global DTaP and Tdap Vaccines Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 32. Global DTaP and Tdap Vaccines Sales by Application (2021-2026) & (W Units) Table 33. Global DTaP and Tdap Vaccines Sales by Application (2027-2032) & (W Units) Table 34. Global DTaP and Tdap Vaccines Sales Market Share by Application (2021-2026) Table 35. Global DTaP and Tdap Vaccines Sales Market Share by Application (2027-2032) Table 36. Global DTaP and Tdap Vaccines Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 37. Global DTaP and Tdap Vaccines Revenue by Application (2021-2026) & (W Units) Table 38. Global DTaP and Tdap Vaccines Revenue by Application (2027-2032) & (W Units) Table 39. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2021-2026) Table 40. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2027-2032) Table 41. Global DTaP and Tdap Vaccines Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 42. Global DTaP and Tdap Vaccines Sales by Region (2021-2026) & (W Units) Table 43. Global DTaP and Tdap Vaccines Sales Market Share by Region (2021-2026) Table 44. Global DTaP and Tdap Vaccines Sales Forecasted by Region (2027-2032) & (W Units) Table 45. Global DTaP and Tdap Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 46. North America DTaP and Tdap Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 47. North America DTaP and Tdap Vaccines Sales by Country (2021-2026) & (W Units) Table 48. North America DTaP and Tdap Vaccines Sales by Country (2027-2032) & (W Units) Table 49. Europe DTaP and Tdap Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 50. Europe DTaP and Tdap Vaccines Sales by Country (2021-2026) & (W Units) Table 51. Europe DTaP and Tdap Vaccines Sales by Country (2027-2032) & (W Units) Table 52. Asia Pacific DTaP and Tdap Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. Asia Pacific DTaP and Tdap Vaccines Sales by Country (2021-2026) & (W Units) Table 54. Asia Pacific DTaP and Tdap Vaccines Sales by Country (2027-2032) & (W Units) Table 55. South America, Middle East and Africa DTaP and Tdap Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. South America, Middle East and Africa DTaP and Tdap Vaccines Sales by Country (2021-2026) & (W Units) Table 57. South America, Middle East and Africa DTaP and Tdap Vaccines Sales by Country (2027-2032) & (W Units) Table 58. Global DTaP and Tdap Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global DTaP and Tdap Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 60. Global DTaP and Tdap Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 61. Global DTaP and Tdap Vaccines Revenue Market Share by Region (2021-2026) Table 62. Global DTaP and Tdap Vaccines Revenue Market Share by Region (2027-2032) Table 63. Johnson & Johnson Company Information Table 64. Johnson & Johnson Business Overview Table 65. Johnson & Johnson DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio Table 67. Johnson & Johnson Recent Development Table 68. Novartis AG Company Information Table 69. Novartis AG Business Overview Table 70. Novartis AG DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Novartis AG DTaP and Tdap Vaccines Product Portfolio Table 72. Novartis AG Recent Development Table 73. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 74. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 75. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio Table 77. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 78. Pfizer Inc Company Information Table 79. Pfizer Inc Business Overview Table 80. Pfizer Inc DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Pfizer Inc DTaP and Tdap Vaccines Product Portfolio Table 82. Pfizer Inc Recent Development Table 83. GlaxoSmithKline Company Information Table 84. GlaxoSmithKline Business Overview Table 85. GlaxoSmithKline DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio Table 87. GlaxoSmithKline Recent Development Table 88. AstraZeneca Company Information Table 89. AstraZeneca Business Overview Table 90. AstraZeneca DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. AstraZeneca DTaP and Tdap Vaccines Product Portfolio Table 92. AstraZeneca Recent Development Table 93. Seqirus Company Information Table 94. Seqirus Business Overview Table 95. Seqirus DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Seqirus DTaP and Tdap Vaccines Product Portfolio Table 97. Seqirus Recent Development Table 98. Sanofi Pasteur Company Information Table 99. Sanofi Pasteur Business Overview Table 100. Sanofi Pasteur DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio Table 102. Sanofi Pasteur Recent Development Table 103. Protein Sciences Corporation Company Information Table 104. Protein Sciences Corporation Business Overview Table 105. Protein Sciences Corporation DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio Table 107. Protein Sciences Corporation Recent Development Table 108. Merck Sharp & Dohme Corp Company Information Table 109. Merck Sharp & Dohme Corp Business Overview Table 110. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio Table 112. Merck Sharp & Dohme Corp Recent Development Table 113. Emergent BioSolutions Inc Company Information Table 114. Emergent BioSolutions Inc Business Overview Table 115. Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio Table 117. Emergent BioSolutions Inc Recent Development Table 118. Astellas Pharma US, Inc Company Information Table 119. Astellas Pharma US, Inc Business Overview Table 120. Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio Table 122. Astellas Pharma US, Inc Recent Development Table 123. Key Raw Materials Table 124. Raw Materials Key Suppliers Table 125. DTaP and Tdap Vaccines Distributors List Table 126. DTaP and Tdap Vaccines Customers List Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. DTaP and Tdap Vaccines Product Image Figure 2. Global DTaP and Tdap Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DTaP and Tdap Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global DTaP and Tdap Vaccines Sales (2021-2032) & (W Units) Figure 5. Global DTaP and Tdap Vaccines Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 DTaP and Tdap Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Tdap Image Figure 9. DTaP Image Figure 10. Td Image Figure 11. Global DTaP and Tdap Vaccines Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global DTaP and Tdap Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global DTaP and Tdap Vaccines Sales Market Share by Type (2021-2032) Figure 14. Global DTaP and Tdap Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global DTaP and Tdap Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global DTaP and Tdap Vaccines Revenue Market Share by Type (2021-2032) Figure 17. Adult Image Figure 18. Pediatric Image Figure 19. Global DTaP and Tdap Vaccines Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global DTaP and Tdap Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global DTaP and Tdap Vaccines Sales Market Share by Application (2021-2032) Figure 22. Global DTaP and Tdap Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global DTaP and Tdap Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global DTaP and Tdap Vaccines Revenue Market Share by Application (2021-2032) Figure 25. North America DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 26. North America DTaP and Tdap Vaccines Sales Market Share by Country (2021-2032) Figure 27. U.S. DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 28. Canada DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 29. Mexico DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Europe DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Europe DTaP and Tdap Vaccines Sales Market Share by Country (2021-2032) Figure 32. Germany DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 33. France DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 34. U.K. DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Italy DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Netherlands DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Asia Pacific DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Asia Pacific DTaP and Tdap Vaccines Sales Market Share by Country (2021-2032) Figure 39. China DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Japan DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 41. South Korea DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Southeast Asia DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 43. India DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Australia DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South America, Middle East and Africa DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 46. South America, Middle East and Africa DTaP and Tdap Vaccines Sales Market Share by Country (2021-2032) Figure 47. Brazil DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South Africa DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Saudi Arabia DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 50. Turkey DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Argentina DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 52. UAE DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Egypt DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Chile DTaP and Tdap Vaccines Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Global DTaP and Tdap Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global DTaP and Tdap Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Figure 58. North America DTaP and Tdap Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Figure 60. Europe DTaP and Tdap Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific DTaP and Tdap Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa DTaP and Tdap Vaccines Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa DTaP and Tdap Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. DTaP and Tdap Vaccines Value Chain Figure 66. Manufacturing Cost Structure Figure 67. DTaP and Tdap Vaccines Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Tdap
  • DTaP
  • Td
Applications
  • Adult
  • Pediatric
Companies covered
  • Johnson & Johnson
  • Novartis AG
  • Lanzhou Institute of Biological Products Co., Ltd
  • Pfizer Inc
  • GlaxoSmithKline
  • AstraZeneca
  • Seqirus
  • Sanofi Pasteur
  • Protein Sciences Corporation
  • Merck Sharp & Dohme Corp
  • Emergent BioSolutions Inc
  • Astellas Pharma US, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global DTaP and Tdap Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global DTaP and Tdap Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global DTaP and Tdap Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global DTaP and Tdap Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global DTaP and Tdap Vaccines Market Dynamics
  1. 2.1 DTaP and Tdap Vaccines Industry Trends
  2. 2.2 DTaP and Tdap Vaccines Industry Drivers
  3. 2.3 DTaP and Tdap Vaccines Industry Opportunities and Challenges
  4. 2.4 DTaP and Tdap Vaccines Industry Restraints
3 DTaP and Tdap Vaccines Market by Manufacturers
  1. 3.1 Global DTaP and Tdap Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global DTaP and Tdap Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global DTaP and Tdap Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global DTaP and Tdap Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global DTaP and Tdap Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global DTaP and Tdap Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global DTaP and Tdap Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global DTaP and Tdap Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 DTaP and Tdap Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 DTaP and Tdap Vaccines Tier 1, Tier 2, and Tier 3
4 DTaP and Tdap Vaccines Market by Type
  1. 4.1 DTaP and Tdap Vaccines Type Introduction
  2. 4.1.1 Tdap
  3. 4.1.2 DTaP
  4. 4.1.3 Td
  5. 4.2 Global DTaP and Tdap Vaccines Sales by Type
  6. 4.2.1 Global DTaP and Tdap Vaccines Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global DTaP and Tdap Vaccines Sales by Type (2021-2032)
  8. 4.2.3 Global DTaP and Tdap Vaccines Sales Market Share by Type (2021-2032)
  9. 4.3 Global DTaP and Tdap Vaccines Revenue by Type
  10. 4.3.1 Global DTaP and Tdap Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global DTaP and Tdap Vaccines Revenue by Type (2021-2032)
  12. 4.3.3 Global DTaP and Tdap Vaccines Revenue Market Share by Type (2021-2032)
5 DTaP and Tdap Vaccines Market by Application
  1. 5.1 DTaP and Tdap Vaccines Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Pediatric
  4. 5.2 Global DTaP and Tdap Vaccines Sales by Application
  5. 5.2.1 Global DTaP and Tdap Vaccines Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global DTaP and Tdap Vaccines Sales by Application (2021-2032)
  7. 5.2.3 Global DTaP and Tdap Vaccines Sales Market Share by Application (2021-2032)
  8. 5.3 Global DTaP and Tdap Vaccines Revenue by Application
  9. 5.3.1 Global DTaP and Tdap Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global DTaP and Tdap Vaccines Revenue by Application (2021-2032)
  11. 5.3.3 Global DTaP and Tdap Vaccines Revenue Market Share by Application (2021-2032)
6 Global DTaP and Tdap Vaccines Sales by Region
  1. 6.1 Global DTaP and Tdap Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DTaP and Tdap Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global DTaP and Tdap Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global DTaP and Tdap Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America DTaP and Tdap Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America DTaP and Tdap Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe DTaP and Tdap Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe DTaP and Tdap Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific DTaP and Tdap Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific DTaP and Tdap Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa DTaP and Tdap Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa DTaP and Tdap Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global DTaP and Tdap Vaccines Revenue by Region
  1. 7.1 Global DTaP and Tdap Vaccines Revenue by Region
  2. 7.1.1 Global DTaP and Tdap Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global DTaP and Tdap Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global DTaP and Tdap Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global DTaP and Tdap Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America DTaP and Tdap Vaccines Revenue (2021-2032)
  8. 7.2.2 North America DTaP and Tdap Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe DTaP and Tdap Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe DTaP and Tdap Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific DTaP and Tdap Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific DTaP and Tdap Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa DTaP and Tdap Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa DTaP and Tdap Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson DTaP and Tdap Vaccines Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG DTaP and Tdap Vaccines Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Lanzhou Institute of Biological Products Co., Ltd
  14. 8.3.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  15. 8.3.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  16. 8.3.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Product Portfolio
  18. 8.3.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  19. 8.4 Pfizer Inc
  20. 8.4.1 Pfizer Inc Company Information
  21. 8.4.2 Pfizer Inc Business Overview
  22. 8.4.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Inc DTaP and Tdap Vaccines Product Portfolio
  24. 8.4.5 Pfizer Inc Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline DTaP and Tdap Vaccines Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca DTaP and Tdap Vaccines Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Seqirus
  38. 8.7.1 Seqirus Company Information
  39. 8.7.2 Seqirus Business Overview
  40. 8.7.3 Seqirus DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Seqirus DTaP and Tdap Vaccines Product Portfolio
  42. 8.7.5 Seqirus Recent Developments
  43. 8.8 Sanofi Pasteur
  44. 8.8.1 Sanofi Pasteur Company Information
  45. 8.8.2 Sanofi Pasteur Business Overview
  46. 8.8.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Pasteur DTaP and Tdap Vaccines Product Portfolio
  48. 8.8.5 Sanofi Pasteur Recent Developments
  49. 8.9 Protein Sciences Corporation
  50. 8.9.1 Protein Sciences Corporation Company Information
  51. 8.9.2 Protein Sciences Corporation Business Overview
  52. 8.9.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Protein Sciences Corporation DTaP and Tdap Vaccines Product Portfolio
  54. 8.9.5 Protein Sciences Corporation Recent Developments
  55. 8.10 Merck Sharp & Dohme Corp
  56. 8.10.1 Merck Sharp & Dohme Corp Company Information
  57. 8.10.2 Merck Sharp & Dohme Corp Business Overview
  58. 8.10.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Product Portfolio
  60. 8.10.5 Merck Sharp & Dohme Corp Recent Developments
  61. 8.11 Emergent BioSolutions Inc
  62. 8.11.1 Emergent BioSolutions Inc Company Information
  63. 8.11.2 Emergent BioSolutions Inc Business Overview
  64. 8.11.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Product Portfolio
  66. 8.11.5 Emergent BioSolutions Inc Recent Developments
  67. 8.12 Astellas Pharma US, Inc
  68. 8.12.1 Astellas Pharma US, Inc Company Information
  69. 8.12.2 Astellas Pharma US, Inc Business Overview
  70. 8.12.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Product Portfolio
  72. 8.12.5 Astellas Pharma US, Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 DTaP and Tdap Vaccines Value Chain Analysis
  2. 9.1.1 DTaP and Tdap Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 DTaP and Tdap Vaccines Production Mode & Process
  6. 9.2 DTaP and Tdap Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 DTaP and Tdap Vaccines Distributors
  9. 9.2.3 DTaP and Tdap Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst